CD4 and HIV-1 infection: The single mutant variants of GRFT (each D30A, D70A or D112A mutant destroying one of the three carbohydrate-binding sites in GRFT) were ∼25- to 70-fold less potent to prevent cell-free HIV-1 infection of CD4+ T-lymphocytes.